Clinical Trials
After a lifetime of treating patients, Dr. David Crouch understood his own illness left little room for optimism as skin cancer returned again and again. As a last resort, he joined a clinical trial of a new immunotherapy that provided him a new lease on life. Today, after 2 years in remission, his mission is to educate people about this cancer and this immunotherapy. Read More ›
“I found out that although my professional experience helped, it did not prepare me to be a caregiver,” says Mark Reisanauer, Oncology Business Unit SVP of Astellas Pharma US. Read More ›
The Jason Carter Clinical Trials Program helps patients with blood cancers find and access clinical trials for free. Read More ›
According to the Cancer Research Institute, only 3% to 6% of eligible patients with cancer participate in clinical trials in the United States. Read the reasons why clinical trials are a great option to consider. Read More ›
By Chase Doyle
Despite the great advances in cancer therapies, only a small proportion of patients with cancer participate in clinical trials today. This has a detrimental effect on the development of new cancer drugs. Read More ›
For patients with cancer, decision-making can feel like a full-time job. The prospect of participating in a clinical trial can become just one more decision that needs to be made. Without the proper information and resources, participating in a clinical trial is often not even an option. Read More ›
The following section features a selection of patient stories submitted to the 2015 Hero of Hope™ Patient Award. These stories illustrate the range of extraordinary patient profiles submitted by patients, family members, friends, and healthcare providers. Read More ›
The role of patients in clinical trials is slowly changing, but enlightening more pharmaceutical companies about the value of the patient’s perspective in designing clinical trials is still a challenge. Read More ›
Clinical trials may be a good treatment option for some patients with cancer, but these trials can be difficult to understand. Read More ›